ParkinsonFranceV1, Main, Exploration, bibRecordById, pubmed:8726542

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease

Identifieur interne : 004661 ( Main/Exploration ); précédent : 004660; suivant : 004662

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease

Auteurs : O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 1996.

RBID : Pascal:96-0305270

Descripteurs français

Pascal (Inist)
- Ropinirole, Agoniste, Dopa, Parkinson maladie, Récepteur dopaminergique D2, Antiparkinsonien, Homme, Chimiothérapie, Efficacité traitement, Association médicamenteuse, Interaction médicamenteuse, Voie orale, Placebo, Aminoacide.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Aged, Agonist, Aminoacid, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, D2 Dopamine receptor, Dopa, Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Double-Blind Method, Drug Therapy, Combination, Drug combination, Drug interaction, Female, Human, Humans, Indoles (administration & dosage), Indoles (adverse effects), Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Motor Activity (drug effects), Oral administration, Parkinson Disease (drug therapy), Parkinson disease, Placebo, Treatment efficiency.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agonists, Indoles, Levodopa.
- chemical , adverse effects : Dopamine Agonists, Indoles.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug effects : Motor Activity.
- drug therapy : Parkinson Disease.
- Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">A. J. Lees</name>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pirtosek, Z" sort="Pirtosek, Z" uniqKey="Pirtosek Z" first="Z." last="Pirtosek">Z. Pirtosek</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fuell, D" sort="Fuell, D" uniqKey="Fuell D" first="D." last="Fuell">D. Fuell</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0305270</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0305270 INIST</idno>
<idno type="RBID">Pascal:96-0305270</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001803</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001843</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001636</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001636</idno>
<idno type="wicri:doubleKey">0362-5664:1996:Rascol O:ropinirole:in:the</idno>
<idno type="wicri:Area/Main/Merge">004F32</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8726542</idno>
<idno type="wicri:Area/PubMed/Corpus">001574</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001574</idno>
<idno type="wicri:Area/PubMed/Curation">001533</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001533</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001533</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001533</idno>
<idno type="wicri:Area/Ncbi/Merge">001E09</idno>
<idno type="wicri:Area/Ncbi/Curation">001E09</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001E09</idno>
<idno type="wicri:doubleKey">0362-5664:1996:Rascol O:ropinirole:in:the</idno>
<idno type="wicri:Area/Main/Merge">004D21</idno>
<idno type="wicri:Area/Main/Curation">004661</idno>
<idno type="wicri:Area/Main/Exploration">004661</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">A. J. Lees</name>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pirtosek, Z" sort="Pirtosek, Z" uniqKey="Pirtosek Z" first="Z." last="Pirtosek">Z. Pirtosek</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fuell, D" sort="Fuell, D" uniqKey="Fuell D" first="D." last="Fuell">D. Fuell</name>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Agonist</term>
<term>Aminoacid</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Drug combination</term>
<term>Drug interaction</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (administration & dosage)</term>
<term>Indoles (adverse effects)</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Oral administration</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ropinirole</term>
<term>Agoniste</term>
<term>Dopa</term>
<term>Parkinson maladie</term>
<term>Récepteur dopaminergique D2</term>
<term>Antiparkinsonien</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Efficacité traitement</term>
<term>Association médicamenteuse</term>
<term>Interaction médicamenteuse</term>
<term>Voie orale</term>
<term>Placebo</term>
<term>Aminoacide</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Fuell, D" sort="Fuell, D" uniqKey="Fuell D" first="D." last="Fuell">D. Fuell</name>
<name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">A. J. Lees</name>
<name sortKey="Pirtosek, Z" sort="Pirtosek, Z" uniqKey="Pirtosek Z" first="Z." last="Pirtosek">Z. Pirtosek</name>
</noCountry>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
</region>
<name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004661 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004661 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:96-0305270
   |texte=   Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.